ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NTP Board Okays concept for New In Vitro study Using Oncogenes

May 10, 1985

In Brief: NCAB To Hear Report On Controversial Special Virus Cancer Program March 19; Centers, Bladder Project Also On Agenda

March 8, 1974

NIH Funding Opportunities Listed

March 13, 2009

NCI Drops Protocol Review Requirement To Encourage firs To List Trials On PDQ

October 24, 1997

Comprehensive Centers Could Lose That Designation By Not Producing

May 30, 1975

Radiotherapy Wing Contractor Dropped

March 27, 1981